The United Kingdom and the United States have concluded a landmark bilateral deal that will keep zero levies on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to raise funding on medicines through the public health system. This commitment secures that tariffs on these crucial products will remain at nothing for a timeframe of the next three years.
This agreement is in response to earlier warnings to significantly raise tariffs on branded pharmaceutical imports, with figures floated reaching double the cost.
"This deal between the United Kingdom strengthens the international landscape for innovative medicines and introduces much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the America, which is clearly the largest destination for leading British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to last September, the UK exported medicines valued at over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that span.
"This deal secures jobs, boosts investment and sets the stage for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement entails several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to raise total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments were more than twenty percent.
Recent Tensions
This agreement takes place against a long-running dispute between the drug companies and the ministers over drug pricing and approval rates.
These tensions were intensified by arguments that US customers were paying several times more for the same drugs than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
